Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma

BACKGROUND: The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) have been implicated as therapeutic targets for head and neck squamous cell carcinoma (HNSCC). Vandetanib is a small-molecule tyrosine kinase inhibitor (TKI) with dual specificity for EGFR...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Klein, Jonah D., Christopoulos, Apostolos, Ahn, Sun M., Gooding, William E., Grandis, Jennifer R., Kim, Seungwon
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675227/
https://ncbi.nlm.nih.gov/pubmed/22307735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.21917
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky